Market Overview:
The global dementia and movement disorder treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of dementia and movement disorders, rising geriatric population, and technological advancements in the field of dementia and movement disorder treatment. On the basis of application, the market is segmented into hospitals, clinics, research institutes & universities, nursing homes & assisted living facilities, retail pharmacies & drug stores, home care settings& others. Geographically, the global dementia and movement disorder treatment market is segmented into North America,, Latin America,, Europe,, Asia Pacific,,and Middle East & Africa,. However,.
Product Definition:
Dementia is a condition that results in the loss of intellectual abilities, such as memory and reasoning, to the point where it interferes with daily life. Movement disorders are conditions that cause abnormal movements. Treatment for dementia and movement disorders usually includes medications and therapy. Treatment for these conditions is important because it can help improve quality of life for people who have them.
MAO Inhibitors (Monoamine Oxidase):
MAO inhibitors are a type of drug that inhibits the action of monoamine oxidase. Monoamine oxidase is an enzyme responsible for removing stored chemical energy from nerve cells and allows them to fire electrical signals. The main function of this enzyme is to prevent brain damage due to lack of oxygen in case of an emergency such as cardiac arrest or being underwater too long.
AChE Inhibitors (Acetylcholinesterase):
The most commonly used AChE inhibitors are donexicam, galantamine, and rivastigmine. Other drugs in this class include scopolamine, nefiracetam, and phenytoin.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other medical facilities. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of dementia and related disorders coupled with increasing awareness about effective treatment options among both patients and healthcare providers. According to data published by Alzheimer¢â‚¬â„¢s Association, over 60 million people are affected by dementia worldwide while over 4 million people are living with Alzheimer's disease or another form of dementia today. In addition, an increase in government initiatives for the early diagnosis and treatment of movement disorders is expected to boost growth during the forecast period (2018-2030).
The others segment includes home healthcare services as well as non-clinical settings including educational institutions or workplaces that provide assistance for individuals suffering from movement problems due to neurological conditions such as Parkinson's disease or Huntington's disease.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and high healthcare expenditure are some of the factors contributing to its growth. In addition, increasing prevalence of neurodegenerative conditions such as Parkinson’s disease (PD) and Alzheimer's disease (AD) is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising geriatric population and growing disposable income coupled with improving healthcare infrastructure in emerging countries such as China & India. Moreover, increasing awareness about mental health disorders among people will also boost regional demand for treatment over the next eight years time frame.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This is expected to drive the demand for dementia and movement disorder treatments in the coming years.
- Rising awareness about dementia and movement disorders: There is a growing awareness about dementia and movement disorders among people across the world. This is likely to boost the demand for these treatments in the near future.
- Growing research and development activities: The pharmaceutical companies are investing heavily in research and development activities for developing new drugs for treating dementia and movement disorders. This is likely to fuel the growth of this market in the coming years.
- Availability of novel therapies: A number of novel therapies are available for treating dementia and movement disorders nowadays, which is expected to boost market growth during the forecast period 2017-2025 . 5) Technological advancements: The technological advancements are helping researchers find better ways to diagnose, treat,and prevent these diseases thereby propelling market growth over forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Dementia and Movement Disorder Treatment Market Research Report
By Type
MAO Inhibitors (Monoamine Oxidase), AChE Inhibitors (Acetylcholinesterase), Glutamate Inhibitors
By Application
Hospitals, Clinics, Others
By Companies
Pfizer, Novartis, Roche, Teva, Amgen, UCB, H. Lundbeck, Eli Lilly, Allergan, Eisai
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
134
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Dementia and Movement Disorder Treatment Market Report Segments:
The global Dementia and Movement Disorder Treatment market is segmented on the basis of:
Types
MAO Inhibitors (Monoamine Oxidase), AChE Inhibitors (Acetylcholinesterase), Glutamate Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Roche
- Teva
- Amgen
- UCB
- H. Lundbeck
- Eli Lilly
- Allergan
- Eisai
Highlights of The Dementia and Movement Disorder Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- MAO Inhibitors (Monoamine Oxidase)
- AChE Inhibitors (Acetylcholinesterase)
- Glutamate Inhibitors
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dementia and Movement Disorder Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dementia is a condition that affects memory and thinking. It can cause problems with activities of daily living, such as dressing, bathing, eating, and getting around. Dementia can also lead to changes in mood or behavior. Movement disorder treatment helps people with dementia or movement disorders stay safe and comfortable while they are moving around. Treatment may include medication, physical therapy, support groups, and home care services.
Some of the key players operating in the dementia and movement disorder treatment market are Pfizer, Novartis, Roche, Teva, Amgen, UCB, H. Lundbeck, Eli Lilly, Allergan, Eisai.
The dementia and movement disorder treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dementia and Movement Disorder Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dementia and Movement Disorder Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dementia and Movement Disorder Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dementia and Movement Disorder Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dementia and Movement Disorder Treatment Market Size & Forecast, 2018-2028
4.5.1 Dementia and Movement Disorder Treatment Market Size and Y-o-Y Growth
4.5.2 Dementia and Movement Disorder Treatment Market Absolute $ Opportunity
Chapter 5 Global Dementia and Movement Disorder Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dementia and Movement Disorder Treatment Market Size Forecast by Type
5.2.1 MAO Inhibitors (Monoamine Oxidase)
5.2.2 AChE Inhibitors (Acetylcholinesterase)
5.2.3 Glutamate Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dementia and Movement Disorder Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dementia and Movement Disorder Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dementia and Movement Disorder Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dementia and Movement Disorder Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dementia and Movement Disorder Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Dementia and Movement Disorder Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dementia and Movement Disorder Treatment Market Size Forecast by Type
9.6.1 MAO Inhibitors (Monoamine Oxidase)
9.6.2 AChE Inhibitors (Acetylcholinesterase)
9.6.3 Glutamate Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dementia and Movement Disorder Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dementia and Movement Disorder Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Dementia and Movement Disorder Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dementia and Movement Disorder Treatment Market Size Forecast by Type
10.6.1 MAO Inhibitors (Monoamine Oxidase)
10.6.2 AChE Inhibitors (Acetylcholinesterase)
10.6.3 Glutamate Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dementia and Movement Disorder Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dementia and Movement Disorder Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dementia and Movement Disorder Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dementia and Movement Disorder Treatment Market Size Forecast by Type
11.6.1 MAO Inhibitors (Monoamine Oxidase)
11.6.2 AChE Inhibitors (Acetylcholinesterase)
11.6.3 Glutamate Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dementia and Movement Disorder Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dementia and Movement Disorder Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Dementia and Movement Disorder Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dementia and Movement Disorder Treatment Market Size Forecast by Type
12.6.1 MAO Inhibitors (Monoamine Oxidase)
12.6.2 AChE Inhibitors (Acetylcholinesterase)
12.6.3 Glutamate Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dementia and Movement Disorder Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dementia and Movement Disorder Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dementia and Movement Disorder Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dementia and Movement Disorder Treatment Market Size Forecast by Type
13.6.1 MAO Inhibitors (Monoamine Oxidase)
13.6.2 AChE Inhibitors (Acetylcholinesterase)
13.6.3 Glutamate Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dementia and Movement Disorder Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dementia and Movement Disorder Treatment Market: Competitive Dashboard
14.2 Global Dementia and Movement Disorder Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Roche
14.3.4 Teva
14.3.5 Amgen
14.3.6 UCB
14.3.7 H. Lundbeck
14.3.8 Eli Lilly
14.3.9 Allergan
14.3.10 Eisai
